ARTICLE | Clinical News
BIOD-531: Phase IIb started
June 8, 2015 7:00 AM UTC
Biodel began the open-label, U.S. Phase IIb Study 3-250 to compare twice daily subcutaneous BIOD-531 vs. Humalog Mix 75/25 insulin lispro protamine/insulin lispro twice daily for 18 weeks in about 130...